We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
-12.9%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$1.16B
AUM Growth
-$119M
Cap. Flow
+$66.8M
Cap. Flow %
5.79%
Top 10 Hldgs %
99.95%
Holding
11
New
1
Increased
3
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$44.5M
2
ALKS icon
Alkermes
ALKS
+$21.7M
3
PEAR
Pear Therapeutics, Inc. Class A Common Stock
PEAR
+$4.47M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$1.49M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$5.37M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
1
Alkermes
ALKS
$8.22B
$327M 28.27%
14,040,000
+827,000
+6% +$21.7M
GILD icon
2
Gilead Sciences
GILD
$162B
$210M 18.16%
2,889,300
-78,000
-3% -$5.37M
IRWD icon
3
Ironwood Pharmaceuticals
IRWD
$696M
$191M 16.54%
16,390,000
– –
BIIB icon
4
Biogen
BIIB
$30B
$154M 13.35%
643,000
– –
INVA icon
5
Innoviva
INVA
$1.55B
$114M 9.88%
6,614,000
– –
AMRN
6
Amarin Corp
AMRN
$299M
$64.9M 5.62%
962,500
+537,500
+126% +$44.5M
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.28B
$55.9M 4.84%
4,039,600
+112,900
+3% +$1.49M
MRSN
8
DELISTED
Mersana Therapeutics
MRSN
$26.7M 2.31%
171,972
– –
VOR icon
9
Vor Biopharma
VOR
$1.15B
$8.21M 0.71%
35,351
– –
PEAR
10
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
$3.1M 0.27%
+500,356
New +$4.47M
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
$583K 0.05%
185,185
– –

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Sarissa Capital Management held 11 positions worth $1.16B, down 9.3% from $1.27B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management deployed $66.8M of net new capital in Q4 2021, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Pear Therapeutics, Inc. Class A Common Stock: 500,356 shares worth $3.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Gilead Sciences, an estimated $5.37M trimmed.

  • Sarissa Capital Management's largest Q4 2021 buy was Pear Therapeutics, Inc. Class A Common Stock: 500,356 shares worth $3.1M.
  • Sarissa Capital Management added most to Amarin Corp in Q4 2021, an estimated $44.5M increase.
  • Sarissa Capital Management's biggest Q4 2021 reduction was Gilead Sciences, cutting an estimated $5.37M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $1.16B portfolio in Q4 2021.
  • Sarissa Capital Management opened 1 new position and closed 0 in Q4 2021.
  • Sarissa Capital Management's portfolio value fell 9.3% quarter-over-quarter to $1.16B.

Based on Sarissa Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.